GEN Exclusives

More »

GEN Poll

More »
Apr 22, 2014

Megamerger Dealzapoppin Poll

You can’t tell the players without a scorecard, especially in biopharma. This week alone, AstraZeneca reportedly turned down a £60 billion ($101 billion) offer from Pfizer, while Novartis, GlaxoSmithKline, and Eli Lilly agreed to overhaul themselves in a series of deals totaling $28.5 billion. Also, Valeant Pharmaceuticals International made a hostile $45.7 billion bid for Botox maker Allergan supported by Allergan’s largest shareholder, investor William Ackman’s Pershing Square Capital Management.

What company not in this week’s M&A headlines do you think will be at the center of a megamerger, acquisition, or partial selloff this year?

Bristol-Myers Squibb
Johnson & Johnson
Merck & Co.
Another company

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Tackling the Global Problem of Fake Medicines

Policy proposals to address the growing global problem of fake medicines include a global agreement, similar to the Framework Convention on Tobacco Control, and stricter national laws to prosecute those who knowingly sell counterfeit medicines. Do you think these steps will be successful?

More »